Background: Future shortages in platelet supply are ex pected in Germany due to demographic changes. A rising cancer incidence will lead to an increasing demand for platelet concentrates (PCs) while the number of potential donors will decrease. Pathogen inactivation (PI) aims to inactivate various infectious agents including emerging pathogens to extend the shelflife of PCs and reduce the frequency of acute transfusion reactions (ATRs). In this context, the clinical and economic impact of PI on platelet transfusion was evaluated. Material and Methods: Model calculations were conducted for 2 scenarios considering different production settings. Frequencies of ATRs were based on literature analyses, platelet and ATR costs on cost analyses. Results: The estimated average costs for ATRs of grade 1 and 2, irrespective of origin, and grade 3 (allergic) were € 104, € 238, and € 1,200, respectively. Approximately 400 PCrelated ATRs per 10 5 transfusions can be avoided, with estimated savings amounting to € 77,000. The total cost increase was calculated to approximately € 30-50 per PItreated PC. Conclusion: PI potentially saves plasma, prolongs shelflife, decreases donor deferral, and reduces ATRs. Model calculations considering clinical and safety benefits of PI show a rational cost increase. The impact of PI should be further evaluated from a societal perspective regarding future blood supply and infectious disease globalization.
well described changes in morphology and biochemistry knownasplateletstoragelesionsexplainswhyfreshplatelets aremoreeffective [6, 7] .Further,plateletproductsfortransfusion are stored at room temperature in plasma or plasma with additive solution under constant agitation, which can promotebacterialgrowth [2, 6] .
Risks of Platelet Transfusion
Theknownclinicalrisksofplatelettransfusionsincludeinfectious complications, immunologic events, and bacterial contamination [2, 6, 8] . Despite thorough donor screening and extensivelaboratorytesting,theriskofthe'windowperiodof infection' remains. Emerging pathogens, which might be transmittedbyplatelets,areanadditionalriskandcanleadto considerableshortagesinbloodsupply.Presentexamplesfor pathogenstransmissiblebybloodtransfusionsrequiringadditionalsafetymeasuresaretheWestNilevirus(WNV),severe acute respiratory syndrome (SARS) virus, Dengue virus, Chikungunya virus, and the parasites Trypanosoma cruzi (Chagas disease), Plasmodium falciparum (malaria) and Introduction Platelettransfusionsareessentialtopreventandtreatbleeding in thrombocytopenic, immunosuppressed patients with cancer, haematological malignancies, bone marrow failure, andafterhaematopoieticstemcellorbonemarrowtransplantation.Theriskofbleedingdependsnotonlyontheplatelet count, but also on the underlying disease, recent haemorrhage, pre-medication potentially influencing platelet function,complicationssuchassepsis,uraemia,anaemia,necrosis in tumour tissue, and defects in coagulation function [1, 2] . Theusualplateletdoseshavebeenintherangeof3-6×10 11 [3] . A recent large randomized trial in haemato-oncological patients(PLADOtrial,ProphylacticPlateletDoseonTransfusionOutcomes)hasshownthatvariationsinplateletdoses between1.1×10 giveninprophylacticplatelettransfusionsareequivalentinthepreventionof bleeding [3] .Factorswhichcanimproveplateletresponsesare the use of ABO-compatible platelets, fresh platelets (stored for48horless),andadministrationoflargedosesofplatelets [4] .Plateletsinthenormalcirculationhaveameanlifespan of7-10daysonly [5, 6] .Thefactthatstoringplateletscauses [14] .Germanhaemovigilancedatahaveshownthat 6PCs,whichcausedfatalinfectionsbetween1997and2009, hadreachedtheendoftheirstoragelifebythetimeoftransfusion.Allfatalinfectionsoccurredinhaematology/oncology patients [14] . To reduce life-threatening septic transfusion reactionscausedbybacterialcontaminations,theshelf-lifeof PCsinGermanywasrestrictedto4×24hfrommidnightof thedayofcollection [12] .In2009and2010,reportedfrequencies of TTBIs were reduced to 4.51 and 4.25 TTBIs per 10 6 transfusedunits,respectively [15] .
Platelet Demand and Supply
From a long-term perspective in Germany, shortages in the supplyofplateletsareexpectedduetodemographicchanges [16, 17] . Platelet consumption has increased continuously between2004and2011by37.3%intotal [18] .Adecreasein the number of potential donors (< 65 years of age) will be accompanied by an increase in elderly patients requiring transfusions [16, 17, 19] . Furthermore, from 2007 to 2050, ariseincancerincidenceby27%hasbeenpredictedforGer-many [16] . The increase in cancer patients will increase the numberofPCsneeded.Investigationsintothedemographic changesin2differentregionsofGermanyrevealeddramatic consequencesforfuturebloodsupply [17, 20] .InNorth-Eastern Mecklenburg Pomerania, the demand for in-hospital bloodtransfusionswillincreasebyapproximately25%from 2005to2020;simultaneouslyblooddonationswilldecreaseby approximately 27%. This adds up to a predicted deficit of 47%forin-hospitalpatients [20] .InSouthernBaden-Wuerttemberg,bloodproductconsumptionforpatientstreatedina tertiarycarecentreandinprimarycarecentresisexpectedto increasefrom2008to2030bymorethan10%andupto30%, respectively.Inparallel,theamountofbloodunitsdonatedin 2030ispredictedtodecreaseby11%comparedto2007 [17] . Theseinvestigationswerecarriedoutonredcellsonly,butit hastobeexpectedthatthese developmentswillbeevenmore distinetinplatelets [17] .
Pathogen Inactivation/Reduction Technologies for PCs
Currently, pathogen inactivation/reduction technologies (PRTs) for PCs comprise 3 methods: pathogen inactivation (PI) with the Intercept Blood System™ (IBS) consisting of treatment with amotosalen and ultraviolet (UV) A light (Cerus Corporation, Concord, CA, USA), the Mirasol ® technology utilizing riboflavin and irradiation with UVB and UVC light (Terumo BCT, Lakewood, CO, USA), and the Theraflex UV™ procedure using irradiation with UVC light alone (MacoPharma, Mouvaux, France) [7, 11] . For the Mirasol method, platelets are suspended in plasma or a combination of plasma and additive solution (SSP+, MacoPharma),andtreatedbytheadditionofriboflavin(vitaminB 2 )and subsequentexposuretoUVBandUVClightof 265-370nmdeliveringadoseof6.2Joules/cm 2 for10minap- proximately.Illuminationleadstophoto-oxidativedamageof nucleicacidsbygenerationofoxygenradicals [7, 11] .Similar tootherPRTs,negativeeffectsonplateletfunctionhavebeen describedforbothUVBandUVClightusedintheMirasol and Theraflex UV technology [21] . With IBS, platelets are suspended in approximately 65% additive solution (InterSol™,FenwalInc.,LakeZurich,IL,USA,orSSP+)and35% plasmabeforeamotosalen,asyntheticpsoralencompound,is added.Thereafter,3Joules/cm 2 UVAlight(320-400nm)are delivered for approximately 5 min resulting in irreversible cross-linkingofnucleicacidsandinhibitionofreplicationand transcription of any DNA or RNA. Un-reacted amotosalen andphotoproductsareremovedbyadsorptiontoacompound adsorptiondevice(CAD)foratleast4handupto16h.With IBS-treated platelets, the remaining risk of TTBI is almost negligible,thefrequencyofATRscanbereduced,andconcomitantly the shelf-life of PCs can be prolonged from 4 to 5daysresultinginwastageratereduction [22] .WhiletheIBS method has been shown to inactivate the broadest range of viruses,bacteria,andprotozoaofallthedescribedtechnologiestolevelsbelowthoselikelytotransmitinfection,noneof themethodscaninactivateprionsduetotheirlackofnucleic acids [11, 23, 24] . Table 2 gives an overview of the benefits anddrawbacksofPRTs.
Clinical and Economic Aspects of PI: Model Calculations
ThemajorpartofPCstransfusedattheUniversityHospital ofMunichcomesfromitsownproductionofapheresisplateletsattheDepartmentofTransfusionMedicine.Over60%of released PCs are used by the Department of Haematology/ Oncology. Therefore, possible clinical and economic aspects of PI were analysed from the perspective of a haematology/ oncology department to estimate benefits and costs on the basis of model calculations. Since in-house production of platelets is not a common approach for German hospitals, 2 scenarios were calculated considering organisational and structural differences. One scenario takes into consideration possiblesavingsbyeliminationoftestsandgammairradiation and plasma saved when using the IBS procedure, the other scenariodoesnot.
Methods
Modelcalculationscanbeusedwhenstudydataonamethodarelimited ormissing,togiveanestimateonbenefitsandcoststobeexpected,and toencouragefurtherresearch.ThemodelcalculationswerebasedonIBS treatment of PCs because this method is to date the most thoroughly studiedandmostwidelyusedinvariouscountries.InGermany,itisthe only PRT technology for PCs approved by the Paul-Ehrlich-Institute (PEI) [22] .
Model Input: Clinical Outcome and Associated Costs
ExperiencehasshownthatclinicalbenefitsafterintroductionofIBSare thereductionofallergic-typeATRsandthepreventionofATRscaused by bacteria in PCs [10, 25] . So far no German studies are available on ATRratessubsequenttotransfusionofIBS-treatedplatelets.Thisdata wasderivedfromaFrenchstudycomprisingmainlyhaematology/oncologypatients.WithoutIBS5.3%andwithIBS1.4%ATRswerereported [25] . To determine treatment costs of the clinical symptoms of ATRs, thesepossiblereactionswereallocatedtograde1-3reactionsaccording to the WHO (grade 1: absence of immediate or long-term vital threat; grade 2: long-term morbidity; grade 3: immediate vital threat; grade 4: deathofthepatient) [25, 26] .Inaddition,forreactionsofgrade2and3 adifferentiationwasmadebetweenallergicandbacterialcauseto capture thereductionofallergicreactionsandthecompleteavoidanceofbacterialreactionsbyPItechnology.ToconsidertheimpactofIBSonthefrequencyofATRsofdifferentdegreesinhaematology/oncologypatients, datafrom2publishedstudieswereused [25, 27] .Treatmentpatternsand therespectivecostsforgrade1ATRs,grade2/3ATRsofallergictype, andgrade2ATRsofbacterialtypewerecalculatedassumingworkload anddrugcostsbasedontheclinicalexpertiseof2expertsfromtheDe-partment of Haematology/Oncology. Costing was based on costs and pricesoftheUniversityHospitalofMunich.Costsforsepsis,thatisgrade 3bacterialATR,werederivedfromtheliterature [28] .Costsofgrade1 ATRsweredeterminedonthebasisofsymptomatictreatmentforurti- 
Discussion
Thecalculatedcostincreaseofapproximately€30-50perPI-treatedPCisassociatedwithpatient-relatedclinicalbenefits. Acostincreaseof€50perPCliesinbetweentheestimated additionalcostsfromcosteffectivenessanalysesforPIinvarious countries [29] [30] [31] . These models refer to known risks of bacterialandviralinfectionsandtherespectivediseaseconsequencesortopotentialinfectiousrisksofre-/emergingpathogenstransmissiblebyPCs,whichwouldallbeavoidedbyPI. Inthecontextofcostsforotheracceptedbloodsafetyinterventions in the developed world, PI for PCs appears to be cost-effectivetomostauthors [29] [30] [31] . TheperspectiveofPCtransfusionforhaematology/oncology patients was chosen because this patient group receives the majority of PCs produced at the University Hospital of Munich.ReportedfrequenciesofATRsfromhaemovigilance dataofvariouscountriesarequitedifferent,butthefewclinical studies available suggest considerably higher rates of ATRs [25, 32] . Critically ill haematology/oncology patients areespeciallysusceptibletosevereinfectionsduetobacterial contamination [14] .ThedemandofPCsforthispatientgroup will increase in the future, whereas supply will be short [16, 17] .Therefore,optimaluseofbloodcomponentsisofmajor importance.NationalandEuropeanUnioninitiativesaimto achievethisgoalbyintroductionofvariousmeasuressuchas benchmarking and patient blood management to avoid inappropriate transfusions and wastage [33] . PI could potentiallyaddtothesemeasuresbysavingofplasma,prolongation of shelf-life, decrease of donor deferral, and reduction of ATRs.
cariawithitching,chills,andfeverlasting<24h.Toobtaintheaverage costofasinglegrade1ATR,thefrequencyofsymptomswastakenfrom the study of Osselaer et al. [27] , in which the authors report on the frequencyofsymptomsrelatedtoplatelettransfusionreactions [27] .
Model Input: Platelet Costs ThecostofasingleapheresisPCproducedattheUniversityHospitalof Munichis€284.CostsforIBSmaterialanduseofequipmentfor2PCs amount to € 152 (including value added tax (VAT); official list price) (CerusEuropeB.V.,MHAmersfoort,TheNetherlands).Coststhatcan beomittedbyusingIBSduringin-houseproductionofPCsarethecosts ofgammairradiationandtestsforcytomegalovirus(CMV)andsyphilis ofdonors.Acquisitioncostsforgammairradiationof1conventionalPC are€25,costsforCMVandsyphilistestingare€2.19and€4.07,respectively(acquisitioncosts,staffcosts).DuringtheIBSprocedure,400mlof plasma can be saved per 2 apheresis PCs corresponding to an average valueof€32. Despite the high safety standard achieved in the past for blood products, bacterial contamination of PCs potentially leadingtobacterialsepsisremainsarelevantresidualrisk [6, 9, 13, 15] .Theimplementationofroutinebacterialdetection methods to screen platelets for bacterial contamination can further reduce but not completely eliminate the risk of PCtransmittedbacterialinfection [34] .Bacterialdetectionassays onlydetectlessthan40%ofcontaminatedproducts [35, 36] . Therefore, comprehensive protection from bacterial infectionsincludingfatalsepsistransmittedbycontaminatedPCs remainsthemajorreasonforimplementationofPI.
Results

CostsofATRsofallergicandbacterialoriginaresummarized
The potential of the PI technique with IBS as a tool to ensuresafebloodsupplyinthecaseofsuddenepidemicshas alreadybeendemonstratedontheoccasionofanoutbreakof the Chikungunya virus in an overseas French department [10] .ImplementationofPIinvariouscountriesisinprogress [37] . Centres in Sweden, Belgium and Spain using the IBS technologyarenolongerperformingroutinegammairradiation treatment. The safety and efficacy of IBS-treated PCs and omission of gamma irradiation and CMV screening was alsodemonstratedinaGermansingle-armstudywiththrombocytopenichaematologypatients [38] .Avoidanceofgamma irradiationwouldimprovethequalityofPCsandthelogistics ofplateletinventory.
LimitationsofourmodelcalculationsarethelackofGermandataconcerningtheavoidanceofATRsinapopulation ofhaematology/oncologypatientsbyuseofIBS-treatedPCs comparedtountreated,gamma-irradiatedPCs,andtheestimationofcostsofATRsbyalimitednumberofclinicalexperts.Furtherlimitationsare:lackofGermandatainvestigating staff working time when using the IBS procedure; and lackofdataconcerningchangesinwastageratesbyprolongationofshelf-lifefrom4to5daysandbyprolongationofthe pro ductiontimeforPCswhenusingtheIBSprocedure.Due to the lack of reliable data, 2 model assumptions had to be made. Labour costs for the production of PCs could not be con sidered since no German data on staff working time for proceduresliketestingofbloodproductsandconductingthe IBSprocedurehavebeenpublished.Wastagerateswerenot considered because they seem to be influenced by various parameters like ineffective platelet inventory management, imbalancesintheproductionsupplychain,andoutdating [39] .
AccordingtoPEIdatafrom2011,wastageofPCsattheproducerlevelwas9.36%,5.25%forapheresisPCs,and15.67% forpooledPCs.Wastageratesattheconsumerlevelwereon average 5.63% in those facilities that reported wastage [18] . NopublishedGermandataareavailableevaluatingtheinfluenceofIBStreatmentofPCsandoftheextensionofthePC shelf-lifefrom4to5daysonwastagerates.However,assumingameanwastagerateof12%inGermancentresproducing apheresisplatelets(Junicon ® ,2009,personalcommunication) theaveragewastageratewoulddropbyapproximately2-5% because of the pro longation of shelf-life by 1 day accompanied by savings accordingly. This estimation is, however, basedonBelgiandata [29] .
Inconclusion,PIseemstobeanimportantoptionforhaematology/oncology patients to almost eliminate PC-related septic transfusion reactions, to reduce PC-related allergic transfusion reactions according to literature-derived clinical data, and to prevent the distribution of re-/emerging pathogensinthefuture.ThetotalcostsofimplementingpathogeninactivatedPCsinGermanywouldamounttoapproximately €26millionignoringanypossiblesavingsandpotentialbene-fits. This number can only be interpreted in comparison to othertreatmentexpenditures.Forexample,in2011costsfor 3 tumour necrosis factor (TNF)-alpha inhibitors (adalimumab,etanacerpt,infliximab)amountedtoatotalof€1.04bil-lion [40] . Complete transparency can only be provided once studydataonclinicalbenefitsandresourceconsumptionare availableindefinedpatientpopulations.ThesocietalperspectivehastobeincludedintheevaluationoftheimpactofPI withrespecttofuturedevelopmentsinbloodsupplyandpossibleglobalizationofinfectiousdiseases.
